Actualité - SOLO2

Publications SOLO-2

Communiqué sur les résultats de l'étude SOLO-2

[ Lynparza Phase III SOLO-2 trial shows significant progression-free survival benefit ]

LYNPARZA PHASE III SOLO-2 TRIAL SHOWS SIGNIFICANT PROGRESSION-FREE SURVIVAL BENEFIT Trial studied Lynparza as maintenance treatment for women with BRCA-mutated metastatic ovarian cancer Initial findings show safety profile with Lynparza tablets was consistent with previous studies

SOLO-2 : News Release - October 26th 2016

SOLO2 Steering Committee, Re: SOLO2 (Study code: D0816C00002) A phase III randomized, double-blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients who are in complete or partial response following platinum based chemotherapy

SOLO-2 : Primary Analysis Steering Committee Communication October 26th 2016